In:
Current Medicinal Chemistry, Bentham Science Publishers Ltd., Vol. 27, No. 30 ( 2020-09-08), p. 4945-5036
Abstract:
To date, there is still no approved anti-dengue agent to treat dengue infection in the market.
Although the only licensed dengue vaccine, Dengvaxia is available, its protective efficacy against serotypes 1 and 2 of dengue virus was reported to be lower than serotypes 3 and 4. Moreover,
according to WHO, the risk of being hospitalized and having severe dengue increased in seronegative individuals after they received Dengvaxia vaccination. Nevertheless, various studies had
been carried out in search of dengue virus inhibitors. These studies focused on the structural (C, prM, E) and non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) of dengue
virus as well as host factors as drug targets. Hence, this article provides an overall up-to-date review of the discovery of dengue virus inhibitors that are only targeting the structural and non-structural
viral proteins as drug targets.
Type of Medium:
Online Resource
ISSN:
0929-8673
DOI:
10.2174/0929867326666181204155336
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2020
SSG:
15,3
Permalink